Fresco Capital — 2021 Investments
5 investments dated 2021 · listed companies and verified rows first · show all
Basepair is a SaaS bioinformatics platform that provisions in a customer's own AWS account to store and analyze genomic and next-generation sequencing (NGS) data without moving it, offering point-and-click and API-driven workflows plus interactive visualization.
BiotechCloud ComputingData & InfrastructureNew York, US
Amit U Sinha(Founder)inAmit Sinha(Founder)
Co-investors37 AngelsCarbon SiliconDraper AssociatesEntrepreneurs Roundtable Accelerator (ERA)MetaplanetZ21 Ventures
Enable Us provides buyer enablement capabilities that allow customers to view tailored content, get answers, and make purchases.
AI & Machine LearningEnterprise SoftwareSaaSSales TechSan Francisco, US
Jinal Jhaveri(CEO)inAdam Pearson(Sales & Co-founder)inAndrey Bolaños(CTO & Co-founder)inGalen Li(CPO & Co-founder)inLynn Pietryga(CCO)inEmily Frary(Head of Human Resources)
Co-investorsRebel FundRuna CapitalY CombinatorBessemer Venture PartnersDecent CapitalDragon Capital+8 more
Mero provides software for the commercial property management industry to record and track cleaning and facility data in real time, replacing manual logs and spreadsheets.
IoTPropTechSaaSToronto, CA
JAMES-ANDREW COLE MACDONALD(DIRECTOR, CO-FOUNDER AND PRESIDENT)Cole MacDonald(Co-founder)inNathan Mah(Co-founder)in
Co-investors500 GlobalWomen's Equity Lab
Outvio provides an all-in-one post-purchase software for eCommerce retailers and B2B sellers, covering order fulfilment, shipping, tracking, customer notifications, returns, exchanges, and analytics.
E-commerceLogistics & Supply ChainSaaSMiami, US
Kaidi T(Founder)Juan J. Borras(CEO)inMykyta Bazhenov(CTO)inKaidi Tiitson(COO)
Co-investorsChange VenturesTMT Investments
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Mero Technologies
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




















